Phase I trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

Sponsor:

Alliance for Clinical Trials in Oncology

Sponsor Study ID:

A051901

CTO #:

103979

NCT Number:

NCT04609046

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Brain and Nervous System

Study Objectives:

Determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with HD-MTX and rituximab, with or without nivolumab, as induction treatment of primary CNS lymphoma. Determine the proportion of patients who are able to stay on maintenance therapy with lenalidomide and/or nivolumab for 6 months after induction treatment of primary CNS lymphoma.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)